| Q34728881 | A fundus dystrophy with unusual features |
| Q28279290 | A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features |
| Q77368835 | A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby's fundus dystrophy with unusual clinical features |
| Q73897327 | A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy |
| Q33683363 | A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy |
| Q68091161 | Abnormal dark adaptation and rhodopsin kinetics in Sorsby's fundus dystrophy |
| Q35303077 | Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa |
| Q38266533 | Altering the clinical course of Sorsby fundus dystrophy with the use of anti-vascular endothelial growth factor intraocular therapy |
| Q43972229 | Antiangiogenic therapy in Sorsby's fundus dystrophy without a mutation in the TIMP-3 gene |
| Q38267565 | Atypical sorsby fundus dystrophy with a novel tyr159cys timp-3 mutation |
| Q35239206 | Autosomal recessive Sorsby fundus dystrophy revisited: molecular evidence for dominant inheritance. |
| Q67578084 | Bietti's crystalline fundus dystrophy (author's transl) |
| Q88679486 | Bilateral choroidal neovascular membrane in a young patient with Sorsby fundus dystrophy: the value of prompt treatment |
| Q95407408 | Bilateral macular hemorrhage and retinitis pigmentosa |
| Q61914755 | CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment |
| Q26799529 | Can Novel Treatment of Age-Related Macular Degeneration Be Developed by Better Understanding of Sorsby's Fundus Dystrophy |
| Q46418145 | Choroidal neovascularization in sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide |
| Q80155791 | Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin) |
| Q85949821 | Choroidal neovascularization secondary to sorsby fundus dystrophy treated with intravitreal bevacizumab |
| Q26767086 | Clinical Trials in Retinal Dystrophies |
| Q28365808 | Clinical features of a novel TIMP-3 mutation causing Sorsby's fundus dystrophy: implications for disease mechanism |
| Q21202953 | Cone rod dystrophies |
| Q63317538 | Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus |
| Q64059466 | Empowering Mesenchymal Stem Cells for Ocular Degenerative Disorders |
| Q93025590 | Evaluation of Pro-re-Nata (PRN) and Treat and Extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy |
| Q40753407 | Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis |
| Q73417864 | Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients |
| Q34246591 | Fundus dystrophy with unusual features; a histological study |
| Q34246317 | Further cases of a fundus dystrophy with unusual features |
| Q91325904 | Gene Therapy in Retinal Dystrophies |
| Q38053151 | Gene therapy in animal models of autosomal dominant retinitis pigmentosa |
| Q92276489 | Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa |
| Q97534006 | In vitro stem cell modelling demonstrates a proof-of-concept for excess functional mutant TIMP3 as the cause of Sorsby Fundus Dystrophy |
| Q35618296 | Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature |
| Q91437215 | LONG-TERM VISUAL ACUITY PRESERVATION IN SORSBY FUNDUS DYSTROPHY WITH CORTICOSTEROID TREATMENT |
| Q92639263 | Late-Stage Sorsby Fundus Dystrophy Manifesting Severe Vision Loss in the Absence of Choroidal Neovascularization |
| Q39423311 | Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions |
| Q33676158 | Linkage refinement localises Sorsby fundus dystrophy between markers D22S275 and D22S278. |
| Q47921791 | Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation |
| Q38199019 | Modeling retinal dystrophies using patient-derived induced pluripotent stem cells. |
| Q58728893 | Modulation of three key innate immune pathways for the most common retinal degenerative diseases |
| Q93127430 | Molecular Strategies for RPGR Gene Therapy |
| Q80760485 | Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy |
| Q54103947 | Molecular exploration of the R91W (RPE65 gene) in Tunisian patients with early onset retinal dystrophy and early onset retinitis pigmentosa |
| Q33739682 | Mutations in spliceosomal proteins and retina degeneration |
| Q28236562 | Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy |
| Q28288733 | Night blindness in Sorsby's fundus dystrophy reversed by vitamin A |
| Q37252057 | OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy |
| Q91900302 | Optical Coherence Tomography Angiography Assessed Retinal and Choroidal Microvasculature Features in Patients with Retinitis Pigmentosa: A Meta-Analysis |
| Q91534976 | Optical Coherence Tomography of Animal Models of Retinitis Pigmentosa: From Animal Studies to Clinical Applications |
| Q79411719 | Optical coherence tomography for assessing disease progression in sorsby fundus dystrophy |
| Q33715782 | Prevalence and novelty of PRPF31 mutations in French autosomal dominant rod-cone dystrophy patients and a review of published reports |
| Q33587035 | Probable common origin of a hereditary fundus dystrophy (Sorsby's familial pseudoinflammatory macular dystrophy) in an English and Australian family |
| Q26782162 | Progress and prospects of next-generation sequencing testing for inherited retinal dystrophy |
| Q28279443 | Pseudoinflammatory fundus dystrophy with autosomal recessive inheritance |
| Q43428829 | Pseudoinflammatory fundus dystrophy: a follow-up study |
| Q36008733 | RPGR: Its role in photoreceptor physiology, human disease, and future therapies. |
| Q42560121 | Ranibizumab for the management of Sorsby fundus dystrophy |
| Q38241625 | Recent advances of stem cell therapy for retinitis pigmentosa |
| Q93117685 | Retinal Prostheses and Artificial Vision |
| Q21203028 | Retinitis pigmentosa |
| Q28076321 | Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention |
| Q28304672 | Review: the history and role of naturally occurring mouse models with Pde6b mutations |
| Q73671811 | Rod plateaux during dark adaptation in Sorsby's fundus dystrophy and vitamin A deficiency |
| Q90113063 | Role of FGF and Hyaluronan in Choroidal Neovascularization in Sorsby Fundus Dystrophy |
| Q61914595 | Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis |
| Q63534109 | Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene |
| Q56866629 | Sorsby Fundus Dystrophy |
| Q91404780 | Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism |
| Q35576323 | Sorsby Fundus Dystrophy: Novel Mutations, Novel Phenotypic Characteristics, and Treatment Outcomes. |
| Q90712526 | Sorsby Pseudoinflammatory Fundus Dystrophy |
| Q47894945 | Sorsby fundus dystrophy - A review of pathology and disease mechanisms. |
| Q44564582 | Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. |
| Q43008034 | Sorsby fundus dystrophy presenting with choroidal neovascularisation showing good response to steroid treatment. |
| Q92337769 | Sorsby fundus dystrophy with polypoidal choroidal vasculopathy: Extending TIMP3 phenotypes |
| Q35315477 | Sorsby fundus dystrophy without a mutation in the TIMP-3 gene |
| Q57168304 | Sorsby fundus dystrophy: Insights from the past and looking to the future |
| Q46498563 | Sorsby fundus dystrophy: reevaluation of variable expressivity in patients carrying a TIMP3 founder mutation |
| Q46002279 | Sorsby's Fundus Dystrophy: a case report to raise awareness of the disease and potential future treatments. |
| Q30697455 | Sorsby's fundus dystrophy |
| Q69569261 | Sorsby's fundus dystrophy |
| Q34211400 | Sorsby's fundus dystrophy in a family with a Ser-181-CVS mutation in the TIMP-3 gene: poor outcome after laser photocoagulation. |
| Q34407470 | Sorsby's fundus dystrophy in the British Isles: demonstration of a striking founder effect by microsatellite-generated haplotypes |
| Q73444301 | Sorsby's fundus dystrophy in two Japanese families with unusual clinical features |
| Q28238247 | Sorsby's fundus dystrophy is genetically linked to chromosome 22q13-qter |
| Q44174063 | Sorsby's fundus dystrophy mutant tissue inhibitors of metalloproteinase-3 induce apoptosis of retinal pigment epithelial and MCF-7 cells |
| Q46751935 | Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells |
| Q40752791 | Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix |
| Q77969703 | Sorsby's fundus dystrophy: a case report of 24 years follow-up with electrodiagnostic tests and indocyanine green angiography |
| Q74483859 | Sorsby's fundus dystrophy: a literature review |
| Q78662649 | Sorsby's fundus dystrophy: what does TIMP3 tell us about general mechanisms underlying macular degeneration? |
| Q105088917 | Study of New Mutations in Cone Disorders |
| Q43008612 | Successful photodynamic therapy for subretinal neovascularisation due to Sorsby's fundus dystrophy: 1 year follow up. |
| Q85947594 | Successful treatment of choroidal neovascularization secondary to sorsby fundus dystrophy with intravitreal bevacizumab |
| Q73535482 | TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby's fundus dystrophy |
| Q28279666 | TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights |
| Q91160882 | The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond |
| Q120691188 | The first genetic landscape of inherited retinal dystrophies in Portuguese patients identifies recurrent homozygous mutations as a frequent cause of pathogenesis |
| Q98629083 | The retinal pigment epithelium in Sorsby Fundus Dystrophy shows increased sensitivity to oxidative stress-induced degeneration |
| Q38843222 | Unilateral pigmentary retinopathy--a review of literature and case presentation |
| Q71039462 | [Fundus dystrophy and ceroid-lipofuscinosis] |